Table 4.

Key human pharmacokinetic parameters for selected small-molecule drugs NOT approved for oncology indications

Generic Name	Brand Name	Dose	Dose Unit	Route	infusion	Cmax (uM)	Cmax (ng/ml)	AUC (ng•hr/ml)	Tmax (hr)	T1/2 (hr)	Protein binding
Alfuzosin	UroXatral	10	mg	PO	-	0.035	14	194	8.0	10	82–90%
Aminoglutethimide	Cytadren	500	mg	PO	-	25.4	5900	-	1.5	12.5	21–25%
Celecoxib	Celebrex	400	mg	PO	-	4.60	1752	13049	-	8.8	97%
Chloroquine	Aralen	750	mg	PO	-	0.725	232	8385	3.7	-	55%
Dutasteride	Avodart	0.5	mg	PO	-	0.076	40	-	2–3	840	99%
Finasteride	Proscar	5	mg	PO	-	0.124	46	389	1.8	6	90%
Histrelin acetate	Supprelin	0.0567	mg/day	SC		0.00083	1.1	2318	12	-	70%
Hydroxychloroquine	Plaquenil	200	mg	PO	-	0.35000	117.4	12015	3.8	564	45%
Ibandronate	Boniva	6	mg	IV	30 min	1.02	327	942	0.63	12	86%
Medroxyprogesterone acetate	Provera	20	mg	PO	-	0.0026	1.0	6.95	2.7	12.1	90%
Metformin	Glucophage	1500	mg	PO	-	24.0	3100	18400	1.5	5.98	negligible
Quinacrine	Acrichine	100	mg	PO	-	0.300	120	-	-	-	80–90%
Sildenafil	Viagra	100	mg	PO	-	0.794	377	1295	1.0	2.76	96%
Sirolimus (Rapamycin)	Rapamune	2	mg	PO	-	0.016	15	230	3.5	62	92%
Tacrolimus	Prograf	5	mg	PO	-	0.037	30	243	1.6	34.8	99%
Zalcitabine (Dideoxycytidine)	Hivid	1.5	mg	PO	-	0.119	25	72	0.80	-	<4%

Abbreviations: C_max: maximum plasma concentration; AUC: Area Under the time-plasma Concentration curve; : T_max: Time post-dose of maximum plasma concentration; : T_1/2: Plasma half-life